1 |
2021 |
Amedeo Lonardo, Back to the future: From the history of NAFLD to MAFLD to heterogeneity of disease, Clinical and Translational Discovery. 2021; 1: e9.
https://doi.org/10.1002/ctd2.9 |
2 |
2023 |
Christiane Laue, Ekaterina Papazova, Angelika Pannenbeckers, Jürgen Schrezenmeir. Effect of a Probiotic and a Synbiotic on Body Fat Mass, Body Weight and Traits of Metabolic Syndrome in Individuals with Abdominal Overweight: A Human, Double-Blind, Randomised, Controlled Clinical Study, Nutrients. 2023; 15: 3039.
https://doi.org/10.3390/nu15133039 |
3 |
2023 |
Jayashree Selvalatchmanan, Markus R. Wenk, Anne K. Bendt. 2023; 557.
https://doi.org/10.1002/9783527836512.ch20 |
4 |
2022 |
Nancy de los Ángeles Segura-Azuara, Carlos Daniel Varela-Chinchilla, Plinio A. Trinidad-Calderón. MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis, Frontiers in Medicine. 2022; 8: 774079.
https://doi.org/10.3389/fmed.2021.774079 |
5 |
2024 |
Mahdi Barazesh, Sajad Jalili, Morteza Akhzari, Fouzieyeh Faraji, Ebrahim Khorramdin. Recent Progresses on Pathophysiology, Diagnosis, Therapeutic Modalities,
and Management of Non-alcoholic Fatty Liver Disorder, Current Drug Therapy. 2024; 19: 20.
https://doi.org/10.2174/1574885518666230417111247 |
6 |
2023 |
Li-Li Ren, Xiao-Jun Li, Ting-Ting Duan, Zheng-Hai Li, Jun-Zheng Yang, Ya-Mei Zhang, Liang Zou, Hua Miao, Ying-Yong Zhao. Transforming growth factor-β signaling: From tissue fibrosis to therapeutic opportunities, Chemico-Biological Interactions. 2023; 369: 110289110289.
https://doi.org/10.1016/j.cbi.2022.110289 |